Low Prostate Cancer-Specific Mortality Seen for Men With Localized Disease
Prostate cancer-specific mortality was low for men randomly assigned to active monitoring, prostatectomy, or radiotherapy.
Prostate cancer-specific mortality was low for men randomly assigned to active monitoring, prostatectomy, or radiotherapy.
A multipronged initiative increased germline BRCA mutation testing for patients with ovarian cancer by 31%.
An analysis of data from patients with cancer treated with immune checkpoint inhibitors sought to determine predictors of immune-related adverse effects in these patients.
A presentation at the 2023 ONA Summit reviewed diagnosis and treatment recommendations for uterine, ovarian, and endometrial cancers.
A review of myelofibrosis, including an update on treatment options, was presented at the 2023 ONA Summit.
A discussion of new treatment options that have improved prognosis for patients with bladder cancer and renal cell carcinoma is the focus of a presentation at the 2023 ONA Summit.
Management strategies aimed at improving outcomes in patients with CRC and gastric cancer were presented at the 2023 ONA Summit.
A review of MDS/MDN, including new WHO guidelines and collaborative strategies for managing the care of patients with lower-risk MDS.
A review of patient assessment, treatment options, and management strategies for adverse effects in patients with metastatic HER2-positive breast cancer were presented at the 2023 ONA Summit.
In an oral presentation at the 2023 ONA Summit, a thoracic oncology nurse practitioner reviewed the advances in the treatment of NSCLC and management of related adverse effects.